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HIGHLIGHTS
•	 Mean interfacial surface curvatures have been determined for protein-protein interaction (PPI) partners in 
their complexed and uncomplexed states.
•	 Mean interfacial surface roughnesses have been determined for protein-protein interaction (PPI) partners 
in their complexed and uncomplexed states.
•	 Amino acid compositions have been determined for PPI interface surfaces and these compared with that 
for the average protein surface.
•	 Quantification	of	the	PPI	interfacial	surface	properties	is	used	to	assess	the	druggability	of	these	targets.
* Corresponding Author: 
Email: dave.barlow@kcl.ac.uk (D. Barlow)
ABSTRACT
The targeting of drugs to block protein-protein interactions (PPIs) has attracted great 
interest	over	recent	years.	Such	targets,	however,	have	been	held	to	be	difficult	to	inhibit	
using low molecular weight compounds, and as a consequence they are often branded 
as “undruggable”. This is partly because the interfaces involved are seen to be large, 
and	 the	 fact	 that	 they	 are	 generally	 regarded	 as	 being	 too	 smooth	 and	 too	flat.	 In	 the	
work reported here, a series of quantitative systematic studies have been performed to 
determine the molecular area, roughness, curvature, and amino acid composition of the 
interfacial surfaces of PPIs, to determine the feasibility of designing small molecule drugs 
to inhibit these interactions. The X-ray crystal structures are analysed for a set of 48 
PPIs involving G-protein, membrane receptor extracellular domain, and enzyme-inhibitor 
complexes. The protein partners involved in these PPIs are shown to have much larger 
interfacial	areas	than	those	for	protein-small	molecule	complexes	(≥	900	Å2		vs	~250	Å2 
respectively), and they have interfaces that are fairly smooth (with fractal dimensions 
close	to	2)	and	quite	flat	(with	mean	surface	curvatures	in	the	order	of	±	0.1	Å-1). The 
mean interfacial surface curvatures of the PPI protein partners, however, are seen to 
change	upon	complexation,	some	very	significantly	so.	Despite	the	fact	 that	 the	amino	
acid	 compositions	 of	 the	 PPI	 interface	 surfaces	 are	 found	 to	 be	 significantly	 different	
from that of the average protein surface (with variations according to the type of PPI), it 
is concluded that the prospects for designing low molecular weight PPI inhibitors that act 
in an orthosteric manner remain rather limited.
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Introduction 
Protein-protein interactions (PPIs) play a fundamental 
role in mediating key biological processes, such as the 
mammalian immune response, cell-cell recognition, cell 
proliferation, growth, differentiation, signal transduction 
and	apoptosis.	Changes	 in	 the	specificity	and	affinity	of	
these interactions can lead to cellular malfunction like 
uncontrolled cell growth that results in cancer (Toogood, 
2002;	White	 et	 al.,	 2008;	 Raj	 et	 al.,	 2012;	 Nero	 et	 al.,	
2014).	 Inevitably,	 interest	 has	 arisen	 amongst	 scientists	
within the pharmaceutical industry to develop inhibitors 
of these interactions as therapeutic agents. 
In the past decade, therapeutic proteins such as 
monoclonal antibodies, which target PPIs that are 
accessible to the extracellular environment, have proven 
tremendously successful. However, these macromolecules 
can be expensive and are rarely orally bioavailable. 
Thus, the relative lower cost, ease of use and potential to 
target intracellular PPIs all favour the discovery of small 
synthetic	molecule	(<500	Da)	PPI	modulators (Nero	et	al.,	
2014).	
However, PPIs occur over a large surface area, with 
approximately	750	to	1,500	Å2 buried on each side of the 
protein	interface	(Jones	and	Thornton,	1996;	Conte	et	al.,	
1999).	Moreover,	 the	contact	 surfaces	 involved	at	 these	
interfaces are qualitatively observed to be rather smooth, 
flat	and	featureless,	and	thus	lack	the	deeply	buried	grooves	
and	 pockets	 that	 provide	 for	 the	 high	 affinity	 binding	
sites for small molecules like those found in the substrate 
binding	sites	of	enzymes	(Wells	and	McClendon,	2007).
Despite the ‘undruggability’ of these PPIs, recent 
studies show that there have been some successes seen in 
the development of small molecule inhibitors as cancer 
therapeutics. For example, with the recent case of the 
MDM2/p53	 interaction	 inhibitors,	 there	 are	 interaction	
‘hot spots’ on the PPI surfaces detected, which can provide 
a focus for small molecule inhibitor interactions [Conte et 
al.,	1999;	Vassilev	et	al.,	2004;	Morrow	and	Zhang,	2012;	
Thangudu  et al.,	2012).	At	the	same	time,	there	has	been	
much ongoing research in the challenges governing the 
inhibition of PPIs with small molecule drugs (Arkin and 
Wells,	2004;	Laraia	et	al.,	2015).
The complexes of interest within this study – 
specifically,	those	reflecting	PPIs	which	might	be	targeted	
in	cancer	therapy	–	were	chosen	from	those	identified	by	
Kastritis	et	al.,	(2011)	and	are	binary	complexes	involving	
either G-proteins (OG), receptor extracellular domains 
(OR) or enzyme inhibitors (EI).
The research reported here focuses on providing a 
systematic quantitative analysis of the characteristics of 
these PPI surfaces and the structural changes involved 
at the interfaces following complexation. By testing 
the hypothesis that the PPIs are relatively extensive in 
interface area, have smooth interfaces that are relatively 
flat,	we	aimed	 to	evaluate	 the	difficulty	 in	devising	 low	
molecular weight drugs targeted against PPIs of the kind 
relevant to anticancer drug discovery.
Materials and Methods
A database of 48 PPIs (with X-ray single crystal structures 
determined	 to	 ≤	 2.5	 Å	 resolution)	 was	 compiled	 from	
the	information	provided	by	Kastritis	et	al.,	 (2011).	The	
atomic co-ordinates of the protein complexes of interest 
(together with those of the unbound protein partners) 
were obtained from the Protein Data Bank in Europe 
(PDBe) (Gutmanas et al., 2013)	accessed	at	http://www.
ebi.ac.uk/pdbe/. The molecular surface areas and amino 
acid compositions of the PPI interfaces for the bound and 
unbound proteins involved in G-protein (OG) complexes, 
receptor extracellular domain (OR) complexes, and 
enzyme inhibitor (EI) complexes were obtained using 
PDBePISA	 (Krissinel	 et	 al.,	 2007).	 Mean	 interfacial	
surface curvature values for the component proteins 
involved	 in	 PPI	 complexes	were	 computed	 (in	Å-1, see 
Fig.	 1)	 using	 the	 SurfRace	 program	 (Tsodikov	 et	 al.,	
2002),	employing	a	probe	radius	of	1.2	Å.
The roughness of each PPI interface was computed 
from the fractal dimension of the surface (D), using the 
gradient (2 – D) of a plot of log(A) vs. log(r),	(Lewis	and	
Rees,	 1985)	 where	 A is the molecular surface area of 
the interface atoms (calculated using SurfRace) given a 
spherical probe of radius, r	(varied	over	the	range	0.75	Å	
to	4.0	Å),	using	the	atomic	van	der	Waals	radii	given	by	
Chothia	(1976).	D can take values from 2 (which indicates 
a	perfectly	smooth	surface)	through	to	3	(which	indicates	
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Figure 1 
Figure 1. Cartoon illustrating the relation between the mean surface 
curvature values (k)	 and	 the	 notional	 external	 sphere	 fitted	 to	 the	
surface, with radius = k-1.	 Negative	 values	 of	 k indicate convex 
surfaces, positive values indicate concave surfaces.
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a very rough surface).
Mean interfacial surface curvature and roughness 
values were only calculated for PPI protein partners 
whose structures in the unbound state were determined 
by X-ray crystallography. In cases where the structure of 
the	unbound	form	was	determined	by	NMR,	the	pairwise	
comparisons between its bound and unbound species 
were not performed.
The generic mean frequencies of amino acids across 
protein	 surfaces	 were	 taken	 from	Miller	 et	 al.,	 (1987),	
and the frequencies of the residue types found within PPI 
interfaces were computed using the PDBGoodies utility 
(Hussain	et	al.,	2002).
Pairwise statistical analyses were performed using a 
Student’s	t-test,	and	three-way	comparisons	using	1-way	
ANOVA,	with	statistical	significance	taken	as	p	<	0.05.
Results and Discussion 
Tables	1	and	2	present	the	details	of	the	48	protein-protein	
complexes	considered	for	analysis:	Table	1	shows	details	
for	 the	 12	 G-protein	 (OG)	 and	 7	 receptor	 extracellular	
domain complexes (OR) complexes, and Table 2 shows 
the	details	for	the	29	enzyme	inhibitor	(EI)	complexes.
The interface areas of the PPIs (calculated as half 
the difference in the surface areas of the complexed and 
uncomplexed	 protein	 partners),	 ranged	 from	 476	 Å2 to 
1712	Å2,	 and	were	 significantly	 greater,	 therefore,	 than	
those for protein-small molecule interactions, which 
average	around	500	Å2	(Wells	&	McClendon,	2007).	There	
were	modest	but	statistically	significant	differences	found	
for the interfacial areas of the OG and OR complexes 
versus the EI complexes, with the mean areas determined 
as	952	(±	415)	Å2	and	875	(±	229)	Å2, respectively.
Log-log	plots	of	the	variation	in	PPI	interface	surface	
area as a function of probe radius were in all cases 
linear (with r 2	 ≥	0.95;	cf., Fig. 2), and allowed reliable 
determination of the interfacial surface irregularity/
surface roughness, described by means of the associated 
fractal dimension (D). All the PPI interface surfaces were 
shown	to	be	smooth	(Table	3;	Fig.	3),	with	the	mean	fractal	
dimensions for their unbound protein components of 2.25, 
2.18	and	2.23	for	OG,	OR	and	EI	complexes,	respectively.	
One-way	ANOVA	analysis	for	the	variation	in	the	fractal	
dimensions of the unbound components of the OG, OR 
and	 EI	 complexes	 showed	 no	 significant	 difference	
between the mean interfacial surface roughnesses of the 
three types of complex.
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Figure 2.	 PPI	 interfacial	 molecular	 surface	 area	 (Å2) of the 
uncomplexed	form	of	ADP-ribosylation	factor	1	(PDB	code,	1J2J)	
as a function of probe radius, r	 (Å).	The	 slope	 of	 the	 plot	 allows	
determination of the surface fractal dimension, D, in this case 2.25.
Figure 3.	Space-filling	models	showing	the	ligand	binding	domain	of	the	ephrin	type	B	receptor	4	(a;	PDB	code,	2HLE)	and	the	catalytic	domain	
of	P120	gap	protein	(b;	PDB	code	1WQ1),	with	the	PPI	interface	surfaces	highlighted	yellow.	The	interface	surface	of	the	ephrin	domain	is	fairly	
smooth, with a fractal dimension of D =	2.25,	and	the	P120	protein	interface	surface	is	somewhat	more	rough,	with	D =	2.46.
	 26
Figure 3 
(a) (b)
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Table 1. Data set of G-protein (OG) and receptor extracellular domain (OR) complexes with their unbound components and corresponding 
structural and interfacial properties.
Class
Complex
(PDB 
entry)
Interface 
Area 
(Å2)
Resolution 
(Å)	b
Protein	partner	1
Resolution 
(Å)	b
Number	
of 
residues
Protein partner 2
Resolution 
(Å)	b
Number	
of 
residues
PDB 
entry a Name
PDB 
entry a Name
OG 1A2K 1595 2.50 1QG4	(D)
GTP-binding 
nuclear protein 
Ran
2.50 22 1OUN	(A)
Nuclear	
transport 
factor 2
2.30 27
OG 1E96 590 2.40 1MH1	(A)
Ras-related 
C3	botulinum	
toxin substrate
1.38 18
1HH8	
(B)
Neutrophil	
cytosol factor 
2
1.80 20
OG 1FQJ 899 2.02 1TND	(A)
Guanine 
nucleotide-
binding 
protein G(t) 
subunit 
alpha-1
2.20 24 1FQI	(B)
Regulator 
of G-protein 
signalling	9
1.94 28
OG 1I2M 1389 1.76 1QG4	(A)
GTP-binding 
nuclear protein 
Ran
2.50 34
1A12	
(B)
Regulator of 
chromosome 
condensation
1.70 47
OG 1I4D 703 2.50 1I49	(A) Arfaptin-2 2.80 19
1MH1	
(D)
Ras-related 
C3	botulinum	
toxin substrate 
1
1.38 20
OG 1IBR 1695 2.30 1QG4	(C)
GTP-binding 
nuclear protein 
Ran
2.50 49
1F59	
(D)
Importin 
subunit	beta-1
2.80 54
OG 1J2J 604 1.60 1O3Y	(A)
ADP-
ribosylation 
factor	1
1.50 18
1OXZ	
(B)
ADP-
ribosylation 
factor-binding 
protein	GGA1
1.50 14
OG 1LFD 619 2.10 5P21	(D) GTPase HRas 1.35 18
1LXD	
(C)
Ral guanine 
nucleotide 
dissociation 
stimulator
2.40 15
OG 1NVU 1712 2.20 1LF0	(R) GTPase HRas 1.70 43
2II0	
(S)
Son of 
sevenless 
homolog 
1	variant	
(Fragment)
2.02 57
OG 1WQ1 1420 2.50 6Q21	(R) GTPase HRas 1.95 37
1WER	
(G)
Ras GTPase-
activating 
protein	1
1.60 45
OG 1Z0K 927 1.92 2BME (C)
Ras-related 
protein Rab-
4A
1.57 27
1YZM	
(D) Rabenosyn-5 1.50 24
OG 2FJU 626 2.20 2ZKM	(B)
Phospholipase 
C-beta-2 1.62 19
1MH1	
(A)
Ras-related 
C3	botulinum	
toxin substrate 
1
1.38 14
OR 1E4K 477 2.30 2DTQ (B)
Ig	gamma-1	
chain C region 2.00 15
1FNL	
(C)
Fc-gamma 
RIIIb 1.80 12
OR 1EER 975 1.90 1BUY	(A) Erythropoietin NMR 25
1ERN	
(B)
Erythropoietin 
receptor 2.40 28
OR 1KTZ 493 2.15 1TGK	(A)
Transforming 
growth factor 
beta-3
3.30 10
1M9Z	
(B)
TGF-beta 
receptor 
type-2
1.05 15
157
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Class
Complex
(PDB 
entry)
Interface 
Area 
(Å2)
Resolution 
(Å)	b
Protein	partner	1
Resolution 
(Å)	b
Number	
of 
residues
Protein partner 2
Resolution 
(Å)	b
Number	
of 
residues
PDB 
entry a Name
PDB 
entry a Name
OR 1T6B 967 2.50 1ACC	(X)
Protective 
antigen 2.10 32
1SHU	
(Y)
Anthrax toxin 
receptor 2 1.50 26
OR 1XU1 646 1.90 1U5Y	(B)
TNF	domain	
of	APRIL
0.96 32
1XUT	
(S)
TNFR	13B	
TACI CRD2 
domain
NMR 14
OR 2HLE 1052 2.05 2BBA (A)
Ephrin type-B 
receptor 4 1.65 37
1IKO	
(B) Ephrin-B2 1.92 25
a)	PDB	entry	codes	of	the	protein-protein	complexes	or	their	unbound	protein	partners,	with	the	chain	identifiers	for	partners	1	and	2	given	in	
parentheses. 
b)	Where	the	3-D	structure	of	an	unbound	protein	partner	has	been	determined	by	NMR,	this	is	indicated;	otherwise,	the	resolution	of	the	X-ray	
structure determination is given. 
Table 1. Continued.
A comparison of the mean interfacial surface 
roughness of the bound and uncomplexed protein partners 
involved in OR and EI complexes showed no statistically 
significant	 difference,	 but	 for	 the	 OG	 complexes,	 the	
interfacing surfaces of the partner proteins were found to 
become a little less rough on complexation, with the mean 
interfacial surface fractal dimension decreasing from D = 
2.25 to D = 2.21	(p	=	0.015).
All the PPI interfaces studied were likewise 
determined	to	be	relatively	flat,	with	 their	mean	surface	
curvatures	lying	in	the	range,	-0.12	Å-1	–	0.11	Å-1 (Table 
4). For most of the proteins involved in these PPIs 
(92%),	however,	there	are	differences	between	the	mean	
interfacial surface curvatures of their complexed and 
uncomplexed forms, some of which – like phospholipase 
C 	3	(2FJU),	staphopain	B	(1PXV),	and	Ras-related	Rab- 
4A	 (1Z0K)	 –	 are	 quite	 substantial.	 The	 mean	 absolute 
difference in surface curvatures for all the complexed and 
uncomplexed	species	is	0.028.
Statistical comparisons of the frequencies of the 
20	 different	 amino	 acid	 types	 across	 protein	 surfaces	
in general and their frequencies within PPI interfaces 
revealed	significant	differences	between	OG,	OR	and	EI	
complexes,	 and	 the	 findings	 for	 the	 former	 two	 classes	
of complex are shown graphically in Fig.4. Arginine and 
leucine	show	a	statistically	significant	enrichment	at	 the	
PPI interfaces of OG and OR complexes, whereas EI 
complexes	 show	 a	 significant	 enrichment	 of	 histidine,	
leucine and cysteine (data not shown). The residue types 
that	 are	 significantly	 underrepresented	 at	 PPI	 interfaces	
tend to be those with small and/or polar side chains, 
including alanine and glycine in the PPI interfaces of OR 
	 27
Figure 4 
(a) OR complexes 
(b) OG complexes 
	 27
Figure 4 
(a) OR complexes 
(b) OG complexes 
	 27
Figure 4 
(a) OR complexes 
(b) OG complexes 
	 27
Figure 4 
(a) OR complexes 
(b) OG complexes 
Figure 4. Percentage frequencies of amino acid residue types at protein surfaces and across PPI interfaces. Residue types showing a statistically 
significant	enrichment	across	PPI	interfaces	are	highlighted	red;	those	showing	statistically	significant	depletion	at	PPI	interfaces	are	highlighted	
blue. Data relate to OR complexes (a) and OG complexes (b).
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complexes, alanine and aspartic acid in EI complexes 
(data not shown), and alanine, glycine, and serine in OG 
complexes.
Previous systematic analyses of PPIs have sometimes 
included consideration of complexes whose crystal 
structures	were	determined	to	resolutions	>	2.5	Å	(Jones	
and	Thornton,	1996;	Conte	et	al.,	1999),	and	the	dataset	
selected for study here was deliberately restricted to 
those	whose	 structures	were	 refined	 at	medium	 to	 high	
resolution,	 in	order	 to	give	greater	confidence	in	atomic	
co-ordinates and any quantities derived from these. Many 
of the earlier analyses of PPIs also considered a wider 
spectrum of interaction types than was considered here 
– including those between the sub-units of oligomeric 
proteins, and those between antigens and antibodies 
(Jones	and	Thornton,	1996;	Conte	et	al.,	1999).	Given	that	
these PPIs interfaces are of limited relevance as regards 
the design of (intracellularly acting) anticancer drugs, 
they too were excluded from consideration in the studies 
reported here.
Notwithstanding	 these	 restrictions	 to	 the	 dataset,	
however, and in full accord with the observations 
recorded	by	previous	workers,	we	find	that	the	interfaces	
of the PPIs included in our dataset cover areas around 5 
to	10	times	larger	than	those	seen	in	complexes	involving	
proteins and low molecular ligands. Moreover, these 
interfaces are seen to have surfaces that are quite smooth 
and	flat,	with	very	 little	 change	 in	 the	 roughness	of	 the	
relevant surfaces of the protein partners in their transition 
from their unbound to bound states.
Targeting of these interfaces using non-protein ligands 
that bind across the whole interface area would thus 
require compounds of relatively high molecular weight, 
which would then preclude their administration via the 
oral route (given that such drugs would ideally have 
molecular	weights	<	500	Da	 (Lipinski	et	 al.,	2001)).	 In	
addition, because the PPI interfaces are so smooth (and 
also	 quite	 flat),	 these	 high	 molecular	 weight	 ligands	
would of necessity bind to the target protein surface 
with around half of their structure remaining exposed 
to the surrounding solvent, and this would greatly limit 
the entropic contribution to the free energy of their 
complexation	provided	 through	desolvation.	While	such	
a	 deficiency	 might	 be	 mitigated	 if	 the	 PPI	 interfaces	
involved	 significant	 numbers	 of	 charged	 and	 polar	
groups which would allow for extensive electrostatic and 
hydrogen bond interactions, our analysis of the amino 
acid composition of the PPI interface surfaces shows that 
this is not generally the case. Most of the PPI interface 
surfaces are depleted in small polar residues (like serine, 
threonine),	and	they	are	also	often	deficient	in	the	charged	
residues, lysine and glutamic acid, although the interface 
surfaces in OG and OR complexes are enriched in 
arginine, and EI complexes are enriched in histidine.
It has been proposed, however, that low molecular 
weight	PPI	inhibitors	of	high	affinity	can	be	successfully	
achieved provided they are targeted to bind to the 
interfaces’ key ‘hot spot’ residues (Bogan and Thorn, 
1998;	 Wells	 and	 McClendon,	 2007;	 Thangudu	 et	 al.,	
2012;	Cukuroglu	et	al.,	2014).	It	should	be	noted	though	
that even if this is so, the resulting enthalpic contribution 
to the free energy of complexation is very unlikely to 
compensate	the	fact	that	van	der	Waals	interactions	will	
be far fewer than for similar-sized ligands binding within 
buried pockets, and unlikely also to compensate for the 
minimal	contribution	made	to	binding	affinity	by	ligand	
desolvation.
To	further	compound	the	issue,	we	find	that	virtually	
all the proteins involved in the PPIs studied here undergo 
changes in their mean interfacial surface curvature upon 
complexation, and these changes – taken together with 
the changes in interface residue conformation shown by 
Kastritis	 et	 al.	 (2011)	 –	would	 pose	 problems	 not	 only	
for	 the	 identification	of	so-called	‘hot	spot’	residues	but	
problems too for the quantitative assessment of putative 
ligand	binding	affinities.
Conclusions 
We	 thus	 note	 that	 while	 various	 reviews	 have	 reported	
recent good progress in the design of PPI inhibitors 
(Corbi-Verge	and	Kim,	2016),	with	successes	cited	where	
molecules	have	been	taken	into	clinical	trials	(Nero	et	al.,	
2014;	Laraia	et	al.,	2015),	we	note	too	that	the	molecular	
weights of these compounds are still quite high (typically 
around	 1000	 to	 1500	 Da),	 and	 all	 of	 the	 compounds	
(assuming they are even successful in trials) are thus 
likely to be formulated for parenteral (and not oral) use. 
The large size of these compounds can also be expected to 
result in them having a rather low membrane permeability, 
and their high numbers of hydrogen bond donor and 
acceptor groups may mean that they will likely satisfy the 
pharmacophores of a great number of off-target proteins, 
leading to innumerable side-effects. Moreover, many of 
these compounds are shown to bind as allosteric (rather 
than orthosteric) inhibitors, and so their inhibitory activity 
is explained not by their binding at the PPI interface but 
by their binding elsewhere on the protein surface and 
thereby triggering a conformational change in the protein, 
which then indirectly interferes with the protein-protein 
interaction.	 Taken	 in	 conjunction	with	 the	 observations	
that are recorded here, therefore, the prospects for 
successful design of orthosteric PPI inhibitors for use in 
cancer therapy would seem very limited.
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Table 3. Interfacial surface roughness/fractal dimension (D) of PPI protein partners.
Class PDB code (chain id) Component
Fractal Dimension (D)
Unbound Bound
EI 1ACB	(E) Chymotrypsinogen A 2.27 2.41
EI 1AVX	(A) Trypsin 2.34 2.36
EI 1AVX	(B) Trypsin inhibitor A 2.17 2.16
EI 1BRS	(A) Ribonuclease 2.21 2.22
EI 1BVN	(P) Pancreatic alpha-amylase 2.39 2.30
EI 1EMV	(B) Colicin-E9 2.14 2.15
EI 1EZU	(D) Anionic trypsin-2 2.31 2.27
EI 1F34	(A) Pepsin A 2.18 2.33
EI 1F34	(B) Major	pepsin	inhibitor	3 2.23 2.19
EI 1GL1	(A) Chymotrypsinogen A 2.23 2.31
EI 1HIA	(B) Glandular Kallikrein 2.37 2.41
EI 1HIA	(I) Hirustasin 2.18 2.17
EI 1JIW	(P) Alkaline metalloproteinase 2.33 2.37
EI 1JTG	(A) Beta-lactamase TEM 2.15 2.19
EI 1JTG	(B) Beta-lactamase inhibitory protein 2.19 2.27
EI 1NB5	(D) Pro-cathepsin H 2.16 2.17
EI 1OPH	(A) Alpha-1-antitrypsin 2.13 2.17
EI 1OPH	(B) Cationic trypsin 2.24 2.35
EI 1PPE	(E) Cationic trypsin 2.31 2.37
EI 1PPE	(I) Trypsin	inhibitor	1 2.19 2.14
EI 1PXV	(A) Staphopain B 2.50 2.18
EI 1PXV	(C) Staphostatin B 2.15 2.16
EI 1R0R	(E) Subtilisin Carlsberg 2.22 2.22
EI 1R0R	(I) Ovomucoid 2.13 2.13
EI 1UUG	(C) Uracil-DNA	glycosylase 2.17 2.23
EI 1UUG	(D) Uracil-DNA	glycosylate	inhibtor 2.20 2.25
EI 2ABZ	(A) Carboxypeptidase	A1 2.29 2.30
EI 2ABZ	(C) Metallocarboxypeptidase inhibitor 2.21 2.19
EI 2B42 (A) Xylanase inhibitor 2.22 2.30
EI 2B42 (B) Xylanase 2.23 2.45
EI 2J0T	(B) Interstitial collagenase 2.24 2.25
EI 2O3B	(A) Nuclease 2.19 2.16
EI 2OUL	(B) Chagasin 2.19 2.18
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Class PDB code (chain id) Component
Fractal Dimension (D)
Unbound Bound
EI 2PTC (I) Panctreatic	trypsin	33	inhibitor 2.11 2.12
EI 2SIC (E) Subtilisin	BPN’ 2.27 2.32
EI 2SIC (I) Subtilisin inhibitor 2.17 2.09
EI 2SNI	(E) Subtilisin	BPN’ 2.37 2.30
EI 2SNI	(I) Subtilisin-chymotrypsin inhibitor 2A 2.13 2.13
EI 2UUY	(A) Cationic trypsin 2.23 2.33
EI 2UUY	(B) Tryptase inhibitor 2.08 2.10
EI 3SGB	(E) Streptogrisin-B 2.24 2.24
EI 3SGB	(I) Ovomucoid 2.12 2.09
EI 4CPA (B) Carboxypeptidase 2.36 2.38
OG 1A2K	(A) Nuclear	transport	factor	2 2.34 2.32
OG 1A2K	(D) GTP-binding nuclear protein Ran 2.28 2.20
OG 1E96	(A) Ras-related	C3	botulinum	toxin 2.14 2.17
OG 1E96	(B) Neutrophil	cytosol	factor	2 2.26 2.19
OG 1FQJ	(A)
Guanine nucleotide-
binding protein G(t) 
subunit	alpha-	1
2.22 2.16
OG 1FQJ	(B) Regulator of G-protein 
signalling	9
2.17 2.24
OG 1I2M	(A) GTP-binding nuclear protein Ran 2.23 2.26
OG 1I2M	(B) Regulator of chromosome condensation 2.29 2.22
OG 1I4D	(D) Ras-related	C3	botulinum	
toxin	substrate	1
2.29 2.14
OG 1IBR	(C) GTP-binding nuclear protein Ran 2.28 2.13
OG 1J2J	(A) ADP-ribosylation	factor	1 2.21 2.26
OG 1J2J	(B) ADP-ribosylation factor-
binding	protein	GGA1
2.15 2.20
OG 1LFD	(C) Ral guanine nucleotide dissociation stimulator 2.15 2.12
OG 1LFD	(D) GTPase HRas 2.27 2.28
OG 1NVU	(S) Son of sevenless homolog 
1	variant	(fragment)
2.30 2.34
OG 1NVU	(R) GTPase HRas 2.30 2.19
Table 3. Continued.
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Class PDB code (chain id) Component
Fractal Dimension (D)
Unbound Bound
OG 1WQ1	(G) Ras GTPase- activating 
protein	1
2.46 2.32
OG 1Z0K	(C) Ras-related protein Rab-4A 2.24 2.15
OG 1Z0K	(D) Rabenosyn-5 2.19 2.10
OG 2FJU	(A) Ras-related	C3	botulinum	
toxin	substrate	1
2.29 2.23
OG 2FJU	(B) Phospholipase C- beta- 2 2.15 2.16
OR 1E4K	(B) Ig	gamma-1	chain	C	rgeion 2.20 2.16
OR 1E4K	(C) Fc- gamma RIIIb 2.17 2.15
OR 1EER	(B) Erythropoietin receptor 2.23 2.15
OR 1KTZ	(B) TGF- beta receptor type-2 2.11 2.15
OR 1PVH	(A) Interleukin-6	receptor	subunit beta 2.22 2.22
OR 1T6B	(X) Protective antigen 2.18 2.23
OR 1T6B	(Y) Anthrax toxin receptor 2 2.17 2.17
OR 1XU1	(B) TNF	domain	of	April 2.21 2.17
OR 2HLE	(A) Ephrin type-B receptor 4 2.20 2.25
OR 2HLE	(B) Ephrin-B2 2.17 2.21
Table 4.	Mean	interfacial	surface	curvatures	(Å-1) of PPI proteins.
Table 3. Continued.
Class PDB entry (chain id) Complex
Curvature  (Å-1) Curvature  (Å-1)
Unbound Bound
EI 1AVX	(A) Trypsin 0.04 0.07
EI 1AVX	(B) Trypsin inhibitor A -0.02 -0.02
EI 1F34	(A) Pepsin A 0.03 0.03
EI 1F34	(B) Major	pepsin	inhibitor	3 -0.05 -0.03
EI 1HIA	(B) Glandular Kallikrein 0.11 0.08
EI 1HIA	(I) Hirustasin -0.05 -0.08
EI 1JTG	(A) Beta-lactamase TEM 0.03 0.07
EI 1JTG	(B) Beta-lactamase inhibitory protein 0.00 0.01
EI 1OPH	(A) Alpha-1-antitrypsin -0.09 -0.10
EI 1OPH	(B) Cationic trypsin 0.06 0.05
EI 1PPE	(E) Cationic trypsin 0.05 0.06
EI 1PPE	(I) Trypsin	inhibitor	1 -0.07 -0.06
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Class PDB entry (chain id) Complex
Curvature  (Å-1) Curvature  (Å-1)
Unbound Bound
EI 1PXV	(C) Staphostatin B -0.09 -0.05
EI 1R0R	(E) Subtilisin Carlsberg 0.03 0.01
EI 1UUG	(C) Uracil-DNA	glycosylase -0.03 -0.06
EI 1UUG	(D) Uracil-DNA	glycosylate	inhibitor 0.02 0.00
EI 2ABZ	(A) Carboxypeptidase	A1 0.05 0.06
EI 2ABZ	(C) Metallocarboxypeptidase inhibitor -0.02 -0.04
EI 2B42 (A) Xylanase inhibitor 0.01 0.01
EI 2B42 (B) Xylanase 0.00 0.01
EI 2PTC (E) Cationic trypsin 0.04 0.07
EI 2PTC (I) Panctreatic trypsin inhibitor -0.06 -0.05
EI 2SIC (E) Subtilisin	BPN’ 0.04 0.02
EI 2SIC (I) Subtilisin inhibitor -0.07 -0.09
EI 2SNI	(E) Subtilisin	BPN’ 0.07 0.04
EI 2SNI	(I) Subtilisin-chymotrypsin inhibitor 2A -0.07 -0.06
EI 2UUY	(A) Cationic trypsin 0.09 0.06
EI 2UUY	(B) Tryptase inhibitor -0.12 -0.10
EI 3SGB	(E) Streptogrisin-B 0.02 -0.02
EI 3SGB	(I) Ovomucoid -0.11 -0.08
OG 1A2K	(A) Nuclear	transport	factor	2 0.06 0.02
OG 1A2K	(D) GTP-binding nuclear protein Ran 0.01 0.02
OG 1E96	(A) Ras-related	C3	botulinum	toxin -0.06 -0.04
OG 1E96	(B) Neutrophil	cytosol	factor	2 0.06 0.04
OG 1FQJ	(A)
Guanine nucleotide-
binding protein G(t) 
subunit	alpha-	1
-0.03 -0.02
OG 1FQJ	(B) Regulator of G-protein 
signalling	9
-0.05 -0.06
OG 1I2M	(A) GTP-binding nuclear protein Ran 0.01 -0.01
OG 1I2M	(B) Regulator of chromosome condensation 0.04 -0.04
OG 1I4D	(D) Ras-related	C3	botulinum	
toxin	substrate	1
-0.09 -0.04
OG 1J2J	(A) ADP-ribosylation	factor	1 -0.01 0.04
Table 4. Continued.
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Class PDB entry (chain id) Complex
Curvature  (Å-1) Curvature  (Å-1)
Unbound Bound
OG 1LFD	(C) Ral guanine nucleotide dissociation stimulator -0.08 -0.05
OG 1LFD	(D) GTPase HRas 0.04 0.00
OG 1NVU	(S) Son of sevenless homolog 
1	variant	(fragment)
0.03 0.04
OG 1NVU	(R) GTPase HRas 0.03 -0.01
OG 1WQ1	(R) GTPase HRas -0.03 -0.04
OG 1WQ1	(G) Ras GTPase- activating 
protein	1
0.02 0.05
OG 1Z0K	(D) Rabenosyn-5 -0.06 -0.07
OG 2FJU	(A) Ras-related	C3	botulinum	
toxin	substrate	1
-0.22 -0.06
OG 2FJU	(B) Phospholipase C- beta- 2 -0.05 0.08
OR 1E4K	(B) Ig	gamma-1	chain	C	rgeion -0.05 -0.06
OR 1E4K	(C) Fc- gamma RIIIb -0.03 -0.03
OR 1T6B	(X) Protective antigen -0.03 0.00
OR 1T6B	(Y) Anthrax toxin receptor 2 -0.02 -0.03
OR 2HLE	(A) Ephrin type-B receptor 4 -0.01 0.04
OR 2HLE	(B) Ephrin-B2 -0.05 -0.04
Table 4. Continued.
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